The Safety and Effectiveness of Zidovudine in the Treatment of Patients With Early AIDS Related Complex

Completed · Phase 3

Conditions studied: HIV Infections

In brief

To determine the safety and usefulness of zidovudine (AZT) for the treatment of patients with early symptomatic HIV infection or early AIDS related complex (ARC). The ability of AZT to suppress HIV, to improve body defenses, and to prevent the occurrence or development of AIDS or advanced ARC is being evaluated. In one human study, patients with AIDS or advanced ARC who received AZT had fewer life-threatening infections, improved in weight and performance, and lived longer than patients who received a placebo (inactive medication). Further studies are needed because toxic effects associated with the use of AZT were noted and the long-term effectiveness and toxicity of AZT are still unknown. It is also unknown if AZT will benefit patients with less severe HIV infections such as early ARC or PGL.

Key facts

Study ID

NCT00001011

Run by

National Institute of Allergy and Infectious Diseases (NIAID)

People needed

538

Expected to finish

1995-02-01

Last updated by the study team

2021-11-04

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have a positive antibody to HIV confirmed by a federally licensed ELISA test kit.
• The CD4 cell count must be 201 - 799 cells/mm3 measured on two separate occasions within 60 days at least 72 hours apart prior to study entry (at least 1 of 2 counts and the mean must be < 800 cells/mm3, and at least 1 of 2 counts and the mean must be > 200 cells/mm3). The last count must be within 14 days of study entry.
• Concurrent Medication:
• Allowed:
• Acetaminophen and acetaminophen products but use should be minimized. Continuous use for > 72 hours is discouraged.
• Aerosolized pentamidine.
• Prior Medication:
• Allowed:
• Chemoprophylaxis for Pneumocystis carinii pneumonia with aerosolized pentamidine of 300 mg every 4 weeks through the Respirgard II nebulizer if patient has CD4(+) count < 200 cells/mm3 measured on 2 determinations at least 48 hours apart.

You may not qualify if…

• Concurrent Medication:
• Excluded:
• Other antiretroviral agents, biologic modifiers or corticosteroids.
• Other experimental medications.
• Systemic chemoprophylaxis of Pneumocystic carinii pneumonia (PCP) - aerosolized pentamidine is allowed.
• Prior Medication:
• Excluded:
• Zidovudine (AZT).
• Other antiretroviral agents.
• Excluded within 30 days of study entry:
• Biologic modifiers or corticosteroids.
• Excluded within 60 days of study entry:
• Ribavirin.
• Prior Treatment:
• Excluded within 30 days of study entry:
• Blood transfusions.
• Patients may not have any of the following diseases or symptoms:
• Active oral candidiasis at entry.
• An opportunistic infection or malignancy fulfilling the definition of AIDS (CDC Surveillance Case Definition for Acquired Immunodeficiency Syndrome).
• Temperature > 38.5 degrees C persisting for > 14 consecutive days or > 15 days in a 30-day interval present at entry.
• Chronic diarrhea defined as = or > 3 liquid stools per day, persisting for > 14 days without a definable cause during the past 2 years.
• HIV neurologic disease as manifested by motor abnormalities including impaired rapid eye movements or ataxia; motor weakness in the lower extremities; sensory deficit consistent with a peripheral neuropathy; bladder or bowel incontinence.
• Concurrent neoplasms other than basal cell carcinoma of the skin or in situ carcinoma of the cervix.
• Subjects with hemophilia should be evaluated and treated under the hemophilia protocols, if available at that ACTG.
• Patients may not have any of the following diseases or symptoms:

Where it is running

• Los Angeles County - USC Med Ctr — Los Angeles, California, United States
• UCLA CARE Ctr — Los Angeles, California, United States
• Palo Alto Veterans Adm Med Ctr / Stanford Univ — Palo Alto, California, United States
• Univ of California / San Diego Treatment Ctr — San Diego, California, United States
• Stanford at Kaiser / Kaiser Permanente Med Ctr — San Francisco, California, United States
• Stanford Univ School of Medicine — Stanford, California, United States
• Harbor UCLA Med Ctr — Torrance, California, United States
• George Washington Univ Med Ctr — Washington D.C., District of Columbia, United States
• Univ of Miami School of Medicine — Miami, Florida, United States
• Northwestern Univ Med School — Chicago, Illinois, United States
• Indiana Univ Hosp — Indianapolis, Indiana, United States
• Johns Hopkins Hosp — Baltimore, Maryland, United States
• Harvard (Massachusetts Gen Hosp) — Boston, Massachusetts, United States
• Beth Israel Deaconess - West Campus — Boston, Massachusetts, United States
• Univ of Minnesota — Minneapolis, Minnesota, United States
• St Louis Regional Hosp / St Louis Regional Med Ctr — St Louis, Missouri, United States
• SUNY / Erie County Med Ctr at Buffalo — Buffalo, New York, United States
• City Hosp Ctr at Elmhurst / Mount Sinai Hosp — Elmhurst, New York, United States
• Beth Israel Med Ctr / Peter Krueger Clinic — New York, New York, United States
• Bellevue Hosp / New York Univ Med Ctr — New York, New York, United States
• Cornell Univ Med Ctr — New York, New York, United States
• Saint Luke's - Roosevelt Hosp Ctr — New York, New York, United States
• Mount Sinai Med Ctr — New York, New York, United States
• Univ of Rochester Medical Center — Rochester, New York, United States
• SUNY - Stony Brook — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.